Immune-Related Adverse Events After Combination Checkpoint Blockade: A Short Communication on Steroid-Sparing Practice
DOI:
https://doi.org/10.5281/zenodo.22649312Keywords:
Immune-Related Adverse Events After Combination Checkpoint Blockade;, Translational medicine; Evidence synthesis;, Clinical implementation; Health services researchAbstract
Immune-Related Adverse Events After Combination Checkpoint Blockade is an area of active development in translational
medicine, with evidence that has accumulated unevenly across its component questions. We review the current evidence base for
immune-related adverse events after combination checkpoint blockade, spanning analytical, clinical, implementation, governance,
and economic dimensions, focusing on where practice has converged and where it continues to vary, and set out the practical
considerations relevant to a service considering its adoption. We conclude that selective, context-specific use is best supported by
the evidence currently available, rather than uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.1093/medlaw/fwad013
Brankovic K, Kowalczyk B, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.2196/89834
Castellani R, Ristic C, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.1007/s10916-024-02104-9
Dumitrescu A, Andric D, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3389/fdgth.2026.1896184
Eriksdottir B, Brankovic E, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.3390/diagnostics15162117
Farkas I, Ionescu F, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.4103/jrpp.jrpp_20_65
Grabowski P, Petrescu G, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.3389/fdgth.2026.1763884
Hendriksen W, Wojcik H, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.2196/48297
Ionescu F, Foscarini I, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1007/s00330-025-12031-z
Jankowiak G, Grabowski J, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.3389/fdgth.2026.1699005
Kowalczyk N, Novotna K, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.3389/fdgth.2026.1834800
Lindqvist U, Urbanek L, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.2196/69678
Marchetti D, Doncheva M, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.7759/cureus.46454
Novotna E, Eriksdottir N, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1016/j.ssci.2025.107028
Ostrowski L, Lindqvist O, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.2196/48633
Petrescu S, Szabo P, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1371/journal.pone.0305949
Quintero B, Balogh Q, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.1371/journal.pdig.0000514
Ristic C, Castellani R, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.17219/acem/208596
Szabo J, Jankowiak S, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.7759/cureus.104086
Tarasov Q, Quintero T, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1038/s41746-023-00852-5
Urbanek Z, Zielinski U, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.1016/j.mayocpiqo.2022.09.004
Vasquez A, Alvez V, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.1177/08404704241291226
Wojcik H, Hendriksen W, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.1093/medlaw/fwad013
Zielinski O, Ostrowski Z, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.2196/89834
Andric V, Vasquez A, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.1007/s10916-024-02104-9
Balogh E, Emmerich B, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3389/fdgth.2026.1896184
Chiriac F, Farkas C, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.3390/diagnostics15162117
Doncheva M, Marchetti D, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a validation study". Trials 22(2017): 377-383. DOI: 10.4103/jrpp.jrpp_20_65
Emmerich T, Tarasov E, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.3389/fdgth.2026.1763884
Foscarini C, Chiriac F, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.2196/48297
Alvez D, Dumitrescu A, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1007/s00330-025-12031-z
Brankovic K, Kowalczyk B, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.3389/fdgth.2026.1699005
Castellani R, Ristic C, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.3389/fdgth.2026.1834800
Dumitrescu A, Andric D, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.2196/69678
Eriksdottir B, Brankovic E, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.7759/cureus.46454
Farkas I, Ionescu F, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1016/j.ssci.2025.107028
Grabowski P, Petrescu G, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.2196/48633
Hendriksen W, Wojcik H, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1371/journal.pone.0305949
Ionescu F, Foscarini I, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a scoping review". JAMA 44(2020): 498-506. DOI: 10.1371/journal.pdig.0000514
Jankowiak G, Grabowski J, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.17219/acem/208596
Kowalczyk N, Novotna K, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.7759/cureus.104086
Lindqvist U, Urbanek L, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1038/s41746-023-00852-5
Marchetti D, Doncheva M, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.1016/j.mayocpiqo.2022.09.004
Novotna E, Eriksdottir N, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.1177/08404704241291226
Ostrowski L, Lindqvist O, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.1093/medlaw/fwad013
Petrescu S, Szabo P, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.2196/89834
Quintero B, Balogh Q, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.1007/s10916-024-02104-9
Ristic C, Castellani R, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3389/fdgth.2026.1896184
Szabo J, Jankowiak S, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.3390/diagnostics15162117
Tarasov Q, Quintero T, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.4103/jrpp.jrpp_20_65
Urbanek Z, Zielinski U, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.3389/fdgth.2026.1763884
Vasquez A, Alvez V, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.2196/48297
Wojcik H, Hendriksen W, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1007/s00330-025-12031-z
Zielinski O, Ostrowski Z, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.3389/fdgth.2026.1699005
Andric V, Vasquez A, et al. "Immune-Related Adverse Events After Combination Checkpoint Blockade: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.3389/fdgth.2026.1834800
